# Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

> **NCT02072486** · NA · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 30 (actual)

## Conditions studied

- Advanced Adult Hepatocellular Carcinoma
- Localized Non-Resectable Adult Hepatocellular Carcinoma
- Stage III Childhood Hepatocellular Carcinoma
- Stage IIIA Hepatocellular Carcinoma
- Stage IIIB Hepatocellular Carcinoma
- Stage IIIC Hepatocellular Carcinoma
- Stage IV Childhood Hepatocellular Carcinoma
- Stage IVA Hepatocellular Carcinoma
- Stage IVB Hepatocellular Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Sorafenib Tosylate

## Key facts

- **NCT ID:** NCT02072486
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-18
- **Primary completion:** 2019-07-19
- **Final completion:** 2020-07-19
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02072486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02072486, "Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02072486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*